CERo Therapeutics (CERO): Price-to-Revenue Ratio

Symbol and logo of brand CERo Therapeutics (CERO)

A strong patent moat and a strategic focus on phagocytosis create excellent growth prospects, a trend reflected in the market capitalization-to-revenue ratio on GURU.Markets, where expresses the current value of the metric. CERo Therapeutics (CERO) is scaling its KGEN therapy to capture market share, developing innovative T-cell methods and anticipating a breakthrough in solid tumor treatment through CER-1236 trials.

CERO: CERo Therapeutics Holdings P/S Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for CERo Therapeutics Holdings Inc. (CERO)

- current price and projected stock value:
Price Chart CERo Therapeutics Holdings, Inc.|CERO - Price Target Chart
- stock exchange capitalization data:
Market Value CERo Therapeutics Holdings|CERO - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share CERo Therapeutics|CERO - Book Capitalization|Market Value to Equity Ratio cero.bio|CERO - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital CERo Therapeutics|CERO - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio CERo Therapeutics Holdings|CERO - Company Aggregate Debts|Debts to Book Value CERo Therapeutics Holdings|CERO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings CERo Therapeutics|Intermediate Liquidity Ratio cero.bio
- earnings and valuation multiples information:
CERO - Net Profit|Expected Net Income CERo Therapeutics|CERO - P/E Multiple|Projected Price to Earnings Ratio CERo Therapeutics Holdings, Inc.|CERO - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation CERo Therapeutics Holdings Inc.|CERO - Operating profit EBITDA|Net earnings per share (EPS TTM) CERo Therapeutics|CERO - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months cero.bio|CERO - Net earnings per share growth this year|Expected net earnings per share growth next year CERo Therapeutics
- issuer revenue and sales details:
CERO - Revenue and Sales Volume|Company Future Sales Volume CERo Therapeutics Holdings|CERO - P/S Multiple|Market Cap to Future Revenue Ratio CERo Therapeutics
General company analysis:CERO - cero.bio
Mass-produced product of CERo Therapeutics Holdings, Inc.

The P/S ratio determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of sales. For CERo Therapeutics (CERO), whose operations are focused on high-intensity R&D for T-Chime, this metric reflects market expectations for future commercial success, which is clearly evidenced by the calculated P/S price action.

Who CERo Therapeutics competes with

Price-to-Revenue Ratio LEGN (Legend Biotech Corp)|Price-to-Revenue Ratio Sana Bio SANA|Autolus Therapeutics - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Cartesian Therapeutics)|CLLS: P/S Multiple|Price-to-Revenue Multiple Caribou Biosciences, Inc. CRBU|Price-to-Revenue Ratio Instil Bio, Inc.|Price to Sales genenta.com GNTA|Price-to-Revenue Ratio Century Therapeutics Inc (IPSC)|Jasper Therapeutics, Inc. - Market Cap to Revenue Ratio|P/S Multiple SNTI (Senti Biosciences)|adaptimmune.com (ADAP) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics PLC)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio